ANXA2 and breast carcinoma: A growing body of evidence shows that the dysregulation of ANXA2 expression is associated with tumorigenesis and immunity in a variety of cancers, such as glioma (Li et al., 2021), oral squamous cell carcinoma (Ma and Wang, 2021), pancreatic cancer (Karabulut et al., 2020), colorectal cancer (Hu et al., 2020), breast cancer (Sharma and Jain, 2020), thyroid cancer (Qin et al., 2020), and gastric cancer (Han et al., 2017).